Increased tumor immune infiltration in primary melanoma prior to treatment was associated with significantly improved OS (60% versus 11% 5 year survival) for patients with brisk and non-brisk lymphocytic tumor infiltrates respectively, and a nonsignificant trend for increased PFS [ 4 ].
1
—
—